Fluorouracil

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Actinic Keratoses

Conditions

Actinic Keratoses

Trial Timeline

Aug 1, 2008 → Apr 1, 2011

NCT ID

NCT06712381

About Fluorouracil

Fluorouracil is a phase 1/2 stage product being developed by Sanofi for Actinic Keratoses. The current trial status is completed. This product is registered under clinical trial identifier NCT06712381. Target conditions include Actinic Keratoses.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06712381	Phase 1/2	Completed	Aug 1, 2008	Apr 1, 2011	Actinic Keratoses

Competing Products

20 competing products in Actinic Keratoses

See all competitors

Product	Company	Stage	Hype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel	Sun Pharmaceutical	Phase 1	33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical Cream	Sun Pharmaceutical	Phase 1	33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by Taro	Sun Pharmaceutical	Phase 1	33
Investigational Treatment + Active comparator	Novartis	Phase 2	52
KX01 ointment 1% + Placebo	PharmaEssentia	Phase 3	76
fluorouracil cream 0.5%	Sanofi	Approved	84
Imiquimod + Diclofenac	Viatris	Approved	82
Imiquimod 5 % Cream	Viatris	Phase 2	49
Imiquimod	Viatris	Pre-clinical	20
Aldara (Imiquimod)	Viatris	Phase 3	74
Imiquimod + Diclofenac	Viatris	Approved	82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice daily	Dr. Reddy's Laboratories	Phase 2/3	62
Placebo Gel + LAS41005 + LAS106521	Almirall	Phase 3	72
5-fluorouracil/salicylic acid + Vehicle	Almirall	Phase 3	72
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%	Almirall	Phase 2	47
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel	Almirall	Approved	80
KX2-391 Ointment 1% + Placebo	Almirall	Phase 3	72
Tirbanibulin 2.5 mg ointment	Almirall	Approved	80

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved